Hub : Traits :

Age when periods started (menarche)

1018 significantly associated models · 257 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	41130424	42542658	1	1	2.9e-07	3.7e-06	7.2e-01	99	FOXO6
2	1	43042125	45109101	7	1	2.9e-11	2.5e-11	9.5e-02	94	MED8
3	1	65189751	66803080	2	1	2.7e-10	7.8e-10	1.0e-01	93	LEPROT
4	1	71163715	73435171	1	1	2.6e-14	3.1e-13	2.9e-02	91	NEGR1
5	1	149880483	151715279	2	2	1.1e-07	1.5e-05	6.8e-01	99	C1orf56 ENSA
6	2	15703	963334	1	1	1.9e-09	7.8e-20	8.9e-16	22	SH3YL1
7	2	24348096	25837917	2	1	9.6e-10	1.5e-08	1.7e-02	82	ADCY3
8	2	47224927	48727280	1	1	9.5e-09	2.8e-09	1.2e-01	93	MSH6
9	2	60470926	62394127	4	2	2.8e-13	3.5e-12	4.8e-02	92	LOC339803 PUS10
10	2	152811852	154267276	1	1	2.2e-13	1.5e-12	1.0e+00	100	PRPF40A
11	2	199443880	201021954	1	1	1.5e-23	1.4e-23	1.0e+00	100	SATB2
12	2	202540420	204433184	2	1	3.5e-08	4.6e-07	8.3e-01	100	RP11-686O6.2
13	3	48335857	53623102	51	3	4.1e-13	6.8e-11	9.3e-02	93	DAG1 HEMK1 TMEM110
14	3	127271320	128821807	1	1	1.8e-08	1.2e-08	2.3e-01	96	EEFSEC
15	3	155695485	157118526	1	1	1.1e-07	1.2e-07	1.0e+00	100	TIPARP
16	4	94527983	95955095	1	1	6.0e-11	1.5e-10	1.0e+00	100	HPGDS
17	5	133164490	134784086	3	2	4.7e-20	3.9e-22	3.9e-03	91	SAR1B
18	6	41005502	42598371	4	9	3.0e-10	1.6e-10	1.0e+00	100	BYSL MED20 PRICKLE4
19	6	54344853	55832161	2	1	5.4e-09	8.8e-11	2.4e-03	78	FAM83B
20	6	56123698	57687035	3	1	9.4e-11	1.8e-10	4.2e-01	98	BEND6
21	6	75612601	77124675	1	1	1.6e-07	4.7e-08	1.0e+00	100	SENP6
22	6	83573836	85117025	1	1	1.3e-09	9.8e-10	1.4e-01	94	SNAP91
23	6	100257579	102026932	2	1	7.5e-12	4.1e-12	1.0e+00	100	ASCC3
24	6	104478130	106323464	4	11	7.9e-77	1.1e-112	NaN	NaN	BVES HACE1 LIN28B POPDC3
25	6	108183628	109704062	1	1	1.4e-07	2.2e-10	3.4e-04	68	FOXO3
26	6	125970401	127355237	1	1	3.5e-16	1.3e-16	1.0e+00	100	CENPW
27	6	146826657	148410391	2	1	2.6e-08	2.2e-08	2.8e-01	96	STXBP5
28	6	151030107	152470136	2	1	2.1e-09	1.3e-08	7.0e-02	90	RMND1
29	7	32098935	33489728	1	1	3.0e-07	2.9e-06	2.0e-01	92	RP11-225B17.2
30	7	73425238	75842792	12	4	4.8e-13	3.3e-10	NaN	NaN	PMS2P3 POM121C STAG3L2
31	7	99008415	100411278	1	1	2.4e-07	8.8e-07	2.0e-01	93	TAF6
32	9	110998007	112581047	5	1	1.2e-10	1.6e-09	7.8e-01	100	C9orf5
33	9	126844856	128643415	2	3	2.1e-10	2.1e-11	7.9e-08	36	OLFML2A PPP6C
34	10	64195778	65606229	1	1	1.3e-07	4.6e-07	1.0e+00	100	NRBF2
35	10	96682514	98113333	2	2	3.7e-09	3.6e-17	3.4e-07	63	ALDH18A1 CC2D2B
36	10	122989048	124407934	1	1	1.4e-07	1.9e-06	6.8e-03	68	RP11-500G22.2
37	11	7714238	9679183	6	1	7.4e-13	1.8e-15	1.7e-04	78	RP11-152H18.3
38	11	12611333	14105497	1	1	6.7e-08	5.2e-15	1.5e-08	48	ARNTL
39	11	16532857	18068163	1	1	7.8e-11	1.1e-10	1.8e-05	56	NUCB2
40	11	27792891	28602221	2	1	2.0e-09	4.7e-08	6.9e-01	100	KIF18A
41	11	42881882	44596817	2	1	5.1e-09	2.0e-10	6.7e-04	71	RP11-613D13.5
42	11	46543524	48485877	10	7	3.1e-12	1.7e-09	1.0e+00	100	C1QTNF4 MADD MTCH2 NDUFS3 NR1H3
43	11	64948277	66333072	3	1	9.1e-09	6.6e-08	1.0e+00	100	FIBP
44	11	77027574	78979645	4	1	1.0e-09	6.7e-10	6.9e-03	81	GAB2
45	11	100624096	102570548	2	1	4.8e-17	1.3e-18	1.0e+00	100	TRPC6
46	11	122058476	123525464	2	2	2.6e-32	4.2e-33	1.0e+00	100	C11orf63
47	12	48605088	50000387	1	1	1.4e-07	5.4e-07	2.3e-01	94	CCDC65
48	12	120502726	122037099	1	1	1.8e-07	1.2e-07	7.8e-03	75	SPPL3
49	13	39533590	41063028	1	2	1.6e-07	1.8e-09	4.8e-03	78	COG6
50	14	60168943	61664530	1	1	7.1e-09	2.1e-15	3.4e-08	52	C14orf39
51	14	100104329	101533384	2	2	4.0e-11	7.1e-16	2.3e-01	98	WARS WDR25
52	15	40778506	42301497	5	1	9.1e-14	5.3e-12	1.2e-01	95	CHP
53	15	59941722	61470359	2	2	7.9e-11	2.3e-17	5.8e-05	78	ANXA2 NARG2
54	15	63687200	65137171	1	1	3.0e-07	4.0e-07	1.0e+00	100	SNX1
55	15	67138238	68789191	2	1	1.2e-09	1.9e-09	4.1e-02	88	MAP2K5
56	15	88358250	89773505	1	1	3.9e-13	1.2e-13	4.6e-02	93	DET1
57	16	13697975	14759768	1	1	2.0e-08	1.9e-19	1.2e-12	38	RP11-65J21.3
58	16	19022448	20596558	4	1	3.0e-10	1.2e-09	1.0e+00	100	GPRC5B
59	16	28825605	31026427	21	1	5.1e-12	2.8e-09	1.7e-01	95	ASPHD1
60	16	52828325	54235440	1	1	3.8e-09	1.7e-38	4.5e-31	20	AKTIP
61	16	68901284	70725815	8	7	1.7e-16	3.8e-23	NaN	NaN	CLEC18A NFAT5 PDXDC2P WWP2
62	17	42413481	43570226	1	1	1.5e-07	8.8e-08	1.5e-01	93	DCAKD
63	17	52350677	54097059	3	1	1.6e-10	1.8e-10	3.1e-01	97	HLF
64	17	78966915	79461486	1	1	6.3e-08	8.4e-08	1.7e-02	80	C17orf89
65	18	2912920	4304557	1	1	8.1e-11	1.1e-11	7.0e-03	84	DLGAP1-AS2
66	18	43698447	46153595	5	7	4.9e-17	2.6e-24	NaN	NaN	HDHD2 PIAS2 SMAD2
67	19	588305	2560423	5	2	1.0e-11	4.8e-11	3.5e-01	98	KLF16 REXO1
68	19	9250370	11140703	4	1	2.0e-23	4.0e-20	1.9e-01	98	OLFM2
69	19	12309739	13720731	1	1	2.0e-07	3.8e-06	9.3e-01	100	GCDH
70	19	14764742	16186772	1	1	2.7e-07	2.5e-07	1.0e+00	100	AKAP8
71	19	17963878	18503019	1	1	3.2e-08	8.6e-08	5.4e-01	99	MAST3
72	19	35448803	36956110	8	1	4.9e-13	1.0e-11	5.4e-02	92	UPK1A
73	21	39849553	41498432	5	1	2.7e-15	1.1e-13	1.9e-02	90	PSMG1
74	22	21798199	23032448	4	1	1.6e-08	5.6e-08	1.9e-01	94	LL22NC03-86G7.1
75	22	31195775	32708691	1	1	2.4e-07	1.4e-07	9.7e-04	61	SFI1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.51	2	0	0.0	0.00	1.0e+00	LL22NC03-86G7.1 TMEM110
Bipolar Disorder or Schizophrenia	1.45	4	3	6.7	0.44	5.6e-01	ASPHD1 LL22NC03-86G7.1 SNAP91 TMEM110
Depressed Affect (Nagel 2018)	1.91	6	3	6.7	0.45	3.1e-01	ARNTL ASCC3 C1QTNF4 DAG1 HACE1 MTCH2
Depression (Nagel 2018)	1.47	1	0	0.0	0.00	1.0e+00	MTCH2
Intelligence (Savage-Jansen 2018)	2.38	15	8	17.8	-0.01	9.8e-01	ADCY3 C1QTNF4 CCDC65 CENPW DAG1 FOXO3 FOXO6 MAST3 MED8 MTCH2 NDUFS3 NEGR1 NR1H3 NRBF2 PSMG1
Neuroticism (Nagel 2018)	1.87	6	3	6.7	0.34	4.6e-01	ARNTL ASCC3 C1QTNF4 CENPW GAB2 MTCH2
Schizophrenia (2018)	1.21	2	0	0.0	0.00	1.0e+00	ASPHD1 TMEM110
Schizophrenia vs Biploar Disorder	1.40	2	0	0.0	0.00	1.0e+00	ARNTL DCAKD
Worry (Nagel 2018)	2.05	5	2	4.4	0.66	1.0e-01	C1QTNF4 CENPW MTCH2 SATB2 TMEM110
Alzheimer’s Disease (including proxy)	1.67	1	0	0.0	0.00	1.0e+00	TAF6
Crohns Disease (2017)	1.19	3	1	2.2	0.00	1.0e+00	ADCY3 AKAP8 STAG3L2
Irritable Bowel Disease (IBD)	1.34	4	2	4.4	-0.15	8.5e-01	ADCY3 DAG1 SATB2 STAG3L2
Ulcerative Colitis (UC)	1.30	2	2	4.4	0.00	1.0e+00	DAG1 SATB2
Major Depression (MDD)	1.68	1	1	2.2	0.00	1.0e+00	NEGR1
Reaction Time	1.71	4	2	4.4	0.25	7.5e-01	ADCY3 CCDC65 FOXO3 KIF18A
Verbal and Numeric Reasoning (VNR)	2.35	14	6	13.3	-0.13	6.2e-01	ADCY3 C1QTNF4 CCDC65 CENPW DAG1 FOXO3 FOXO6 MED8 MTCH2 NDUFS3 NEGR1 NR1H3 TMEM110 WWP2
Breast Cancer	1.13	3	2	4.4	0.00	1.0e+00	ADCY3 AKTIP HLF
Prostate Cancer	1.99	1	1	2.2	0.00	1.0e+00	EEFSEC
Age at First Birth	1.57	2	1	2.2	0.00	1.0e+00	DAG1 SAR1B
Body Mass Index (BMI) (2010)	4.15	10	8	17.8	-0.99	1.3e-10	ADCY3 AKTIP C1QTNF4 GPRC5B MAP2K5 MTCH2 NDUFS3 NEGR1 NR1H3 PMS2P3
Crohns Disease (2012)	1.27	1	0	0.0	0.00	1.0e+00	ADCY3
Fasting Glucose	1.45	1	1	2.2	0.00	1.0e+00	MADD
HDL Cholesterol	2.09	5	4	8.9	0.99	1.5e-05	C1QTNF4 MTCH2 NDUFS3 NR1H3 NRBF2
Neuroticism (2016)	1.55	2	0	0.0	0.00	1.0e+00	C1QTNF4 MTCH2
Rheumatoid Arthritis	1.26	1	0	0.0	0.00	1.0e+00	COG6
Schizophrenia (2014)	1.38	5	1	2.2	0.58	3.0e-01	ASPHD1 LIN28B NUCB2 SNAP91 TMEM110
Triglycerides	1.44	1	1	2.2	0.00	1.0e+00	NRBF2
Ulcerative Colitis	1.23	2	0	0.0	0.00	1.0e+00	DAG1 SATB2
Blood Eosinophil Count	1.14	19	10	22.2	-0.03	8.8e-01	ADCY3 ASPHD1 BEND6 CLEC18A COG6 ENSA FIBP HEMK1 LOC339803 MAST3 NFAT5 NUCB2 PDXDC2P REXO1 RMND1 SFI1 SPPL3 TMEM110 WWP2
Blood Platelet Count	1.90	22	17	37.8	0.41	4.5e-02	AKAP8 C1QTNF4 DCAKD EEFSEC FIBP GCDH GPRC5B HEMK1 HLF HPGDS LOC339803 MSH6 MTCH2 NDUFS3 NR1H3 NRBF2 NUCB2 PSMG1 RP11-686O6.2 SNX1 SPPL3 TIPARP
Blood Red Count	7.72	21	16	35.6	-0.58	1.2e-03	ARNTL ASPHD1 BEND6 BYSL CENPW CHP GCDH HLF LL22NC03-86G7.1 MED20 MED8 NFAT5 NRBF2 PMS2P3 PRICKLE4 SNX1 SPPL3 TAF6 TIPARP TMEM110 WWP2
Blood White Count	1.56	14	11	24.4	-0.25	3.5e-01	ADCY3 C1QTNF4 CENPW DAG1 ENSA LEPROT MTCH2 NDUFS3 NR1H3 NRBF2 NUCB2 SPPL3 STXBP5 TIPARP
Heel T-Score	1.57	23	14	31.1	-0.43	1.9e-02	ASPHD1 C11orf63 C14orf39 C1QTNF4 CCDC65 DAG1 DCAKD DET1 ENSA GAB2 GPRC5B HACE1 LIN28B MSH6 NEGR1 NR1H3 PRPF40A RMND1 RP11-500G22.2 RP11-686O6.2 SATB2 STAG3L2 TIPARP
BMI	5.87	42	35	77.8	-0.76	1.9e-10	ADCY3 AKTIP ARNTL ASCC3 ASPHD1 BEND6 C1orf56 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GAB2 GPRC5B HDHD2 HEMK1 KLF16 LEPROT MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 NRBF2 PDXDC2P PIAS2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B SENP6 SNAP91 STAG3L2 TMEM110 WWP2
Height	3.15	59	53	117.8	0.70	6.1e-14	ADCY3 ANXA2 ASPHD1 BEND6 BVES BYSL C11orf63 C14orf39 C1orf56 C1QTNF4 C9orf5 CC2D2B CENPW CHP CLEC18A COG6 DCAKD DET1 DLGAP1-AS2 ENSA FIBP FOXO3 FOXO6 GCDH GPRC5B HACE1 HDHD2 HEMK1 LIN28B LL22NC03-86G7.1 MADD MED20 MED8 MTCH2 NARG2 NDUFS3 NFAT5 NR1H3 NRBF2 NUCB2 OLFM2 OLFML2A PDXDC2P PIAS2 PMS2P3 POPDC3 PRICKLE4 RMND1 RP11-500G22.2 RP11-65J21.3 RP11-686O6.2 SAR1B SENP6 SFI1 SH3YL1 SNAP91 SPPL3 UPK1A WWP2
Waist Hip Ratio (WHR)	2.00	12	5	11.1	0.02	9.6e-01	C14orf39 C9orf5 CENPW HEMK1 MAST3 MED20 NFAT5 PPP6C PRICKLE4 SFI1 TIPARP TMEM110
Systolic Blood Pressure	1.74	16	10	22.2	-0.15	5.5e-01	ADCY3 ARNTL C1QTNF4 DCAKD FIBP FOXO3 KLF16 MED8 MTCH2 NDUFS3 NFAT5 NRBF2 NUCB2 PMS2P3 POM121C STAG3L2
Smoking Status	2.42	8	4	8.9	-0.23	5.5e-01	ASCC3 DAG1 HACE1 MAP2K5 MED8 MSH6 PPP6C WWP2
Allergy or Eczema	1.41	5	2	4.4	-0.40	5.0e-01	CHP DLGAP1-AS2 NEGR1 PUS10 SPPL3
Cardiovascular Disease	1.84	14	7	15.6	-0.78	6.7e-04	ARNTL CHP DCAKD FIBP KLF16 MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 RP11-613D13.5 STAG3L2 TAF6
Hypothyroidism (self reported)	1.16	2	0	0.0	0.00	1.0e+00	C1QTNF4 MTCH2
Respiratory disease	1.27	3	2	4.4	0.00	1.0e+00	DCAKD EEFSEC PSMG1
Type 2 Diabetes (T2D) (2018)	2.09	7	1	2.2	-0.99	2.5e-05	AKTIP CENPW FIBP GCDH NDUFS3 NFAT5 WWP2
Lung FEV1/FVC ratio	1.40	12	6	13.3	-0.02	9.4e-01	ADCY3 BEND6 CENPW EEFSEC FOXO3 GAB2 MSH6 NEGR1 NRBF2 REXO1 RP11-686O6.2 TMEM110
Lung FVC	2.21	18	12	26.7	-0.28	2.0e-01	CENPW CHP DAG1 ENSA FOXO3 FOXO6 HACE1 HEMK1 LIN28B MAP2K5 MSH6 NFAT5 NRBF2 OLFM2 RP11-613D13.5 RP11-686O6.2 SATB2 WWP2
Neuroticism	2.10	10	5	11.1	0.23	5.0e-01	ARNTL ASCC3 C1QTNF4 CENPW DAG1 GAB2 LIN28B MAP2K5 MTCH2 NDUFS3
Chronotype (morning person)	2.89	13	5	11.1	-0.11	6.6e-01	AKTIP BYSL C14orf39 C1QTNF4 DAG1 ENSA FAM83B HDHD2 HEMK1 MED20 NDUFS3 NR1H3 PRICKLE4
Hair Pigment	0.26	8	5	11.1	-0.04	9.2e-01	ADCY3 C1QTNF4 CCDC65 CENPW FOXO3 GAB2 MED20 NUCB2
Tanning	0.27	4	2	4.4	0.39	4.4e-01	ADCY3 GAB2 MED20 TMEM110
Hand grip strength (left)	2.36	8	5	11.1	0.71	1.5e-02	ADCY3 C1QTNF4 GPRC5B LIN28B MTCH2 NDUFS3 NFAT5 WWP2
Number of treatments/medications taken	1.77	3	1	2.2	0.00	1.0e+00	DAG1 LIN28B STAG3L2
Sensitivity / hurt feelings	1.22	1	0	0.0	0.00	1.0e+00	DCAKD
Frequency of depressed mood in last 2 weeks	1.72	2	0	0.0	0.00	1.0e+00	C1QTNF4 MTCH2
Hearing difficulty/problems: Yes	1.24	1	0	0.0	0.00	1.0e+00	SATB2
Relative age of first facial hair	5.86	21	10	22.2	0.96	6.6e-19	ANXA2 BYSL C11orf63 DAG1 DCAKD DET1 ENSA FOXO3 HACE1 HEMK1 HLF HPGDS LIN28B MED20 NARG2 NRBF2 PRICKLE4 PSMG1 RP11-65J21.3 SATB2 SH3YL1
Other serious medical condition/disability diagnosed by doctor	1.49	1	0	0.0	0.00	1.0e+00	PRICKLE4
Systolic blood pressure, automated reading	1.76	12	2	4.4	-0.74	3.5e-03	ARNTL DCAKD FIBP KLF16 MED8 NFAT5 NUCB2 PMS2P3 POM121C SH3YL1 STAG3L2 STXBP5
Supplements: Zinc	1.52	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Metformin	2.16	3	0	0.0	0.47	5.3e-01	C1QTNF4 GCDH NDUFS3
Pack years adult smoking proportion	1.76	1	0	0.0	0.00	1.0e+00	CLEC18A
Impedance of leg (right)	3.23	30	18	40.0	0.52	8.8e-04	ADCY3 AKTIP ASPHD1 C1QTNF4 CCDC65 CLEC18A DAG1 DCAKD FIBP GPRC5B HEMK1 KLF16 LIN28B LL22NC03-86G7.1 MADD MAP2K5 MED20 NEGR1 NFAT5 NR1H3 OLFM2 PDXDC2P PMS2P3 POM121C REXO1 RMND1 SAR1B SFI1 STAG3L2 TMEM110
Leg fat-free mass (left)	2.75	24	17	37.8	-0.12	5.5e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 NR1H3 PMS2P3 POM121C PRICKLE4 REXO1 RMND1 RP11-613D13.5 TMEM110
Trunk fat percentage	4.18	28	17	37.8	-0.67	3.3e-05	ADCY3 AKTIP ARNTL ASPHD1 C11orf63 C1QTNF4 CENPW CLEC18A DCAKD FOXO3 MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 OLFM2 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Hand grip strength (right)	2.02	13	2	4.4	0.76	6.9e-04	ADCY3 C14orf39 C1QTNF4 CHP CLEC18A GPRC5B LIN28B MTCH2 NDUFS3 NFAT5 PDXDC2P REXO1 WWP2
Townsend deprivation index at recruitment	1.92	2	0	0.0	0.00	1.0e+00	KLF16 MAP2K5
Current tobacco smoking	1.96	3	0	0.0	0.99	9.9e-03	C1QTNF4 MTCH2 PPP6C
Maternal smoking around birth	1.90	1	0	0.0	0.00	1.0e+00	MED8
Fed-up feelings	1.41	2	0	0.0	0.00	1.0e+00	ARNTL DAG1
Relative age voice broke	6.81	17	6	13.3	0.98	1.8e-20	ANXA2 C11orf63 DET1 FOXO3 HACE1 HEMK1 HPGDS LIN28B MED20 NFAT5 POM121C PRICKLE4 RP11-65J21.3 SPPL3 STAG3L2 UPK1A WWP2
Taking other prescription medications	2.09	2	1	2.2	0.00	1.0e+00	DAG1 STAG3L2
Heel bone mineral density (BMD) T-score, automated (left)	1.34	5	1	2.2	0.29	6.3e-01	C14orf39 LIN28B RMND1 RP11-686O6.2 TIPARP
High blood pressure	1.90	12	4	8.9	-0.53	6.2e-02	ARNTL DCAKD KLF16 MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 REXO1 STAG3L2 TAF6
Hayfever, allergic rhinitis or eczema	1.44	4	0	0.0	-0.29	7.1e-01	DLGAP1-AS2 NEGR1 PUS10 SPPL3
Sitting height	2.34	19	14	31.1	0.43	2.6e-02	ADCY3 BYSL C14orf39 C1QTNF4 CENPW CHP ENSA FOXO3 FOXO6 LOC339803 MED20 MED8 MTCH2 NDUFS3 NFAT5 RP11-65J21.3 SAR1B TIPARP WWP2
High blood pressure (mother)	1.30	1	0	0.0	0.00	1.0e+00	NUCB2
Body mass index (BMI)	5.53	35	28	62.2	-0.76	7.2e-09	ADCY3 AKTIP ARNTL ASCC3 ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B HEMK1 KLF16 MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 NRBF2 PDXDC2P PIAS2 PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B SENP6 STAG3L2 TMEM110 WWP2
Impedance of leg (left)	3.17	28	17	37.8	0.51	2.3e-03	ADCY3 AKTIP ASCC3 ASPHD1 C1QTNF4 CLEC18A DAG1 DCAKD FIBP GPRC5B HEMK1 KIF18A KLF16 LIN28B MAP2K5 MED20 NEGR1 NFAT5 NR1H3 OLFM2 PDXDC2P PMS2P3 POM121C REXO1 RMND1 SFI1 STAG3L2 TMEM110
Leg predicted mass (left)	2.77	24	17	37.8	-0.12	5.5e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 NR1H3 PMS2P3 POM121C PRICKLE4 REXO1 RMND1 RP11-613D13.5 TMEM110
Trunk fat mass	3.82	31	21	46.7	-0.49	1.7e-03	ADCY3 AKTIP ARNTL ASPHD1 C11orf63 C1QTNF4 CLEC18A DAG1 FOXO3 GPRC5B KLF16 LIN28B MADD MAP2K5 MAST3 MED20 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SH3YL1 STAG3L2 WWP2
Waist circumference	4.23	29	21	46.7	-0.74	7.3e-07	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SAR1B STAG3L2 TIPARP WWP2
Number of incorrect matches in round	1.21	1	1	2.2	0.00	1.0e+00	ASPHD1
Past tobacco smoking	2.20	6	1	2.2	0.36	4.9e-01	HACE1 MAP2K5 MSH6 PPP6C PSMG1 WWP2
Alcohol usually taken with meals	1.98	3	1	2.2	0.00	1.0e+00	MED8 NEGR1 NRBF2
Nervous feelings	1.75	6	0	0.0	0.72	1.1e-01	ARNTL ASPHD1 CENPW MADD SATB2 TMEM110
Frequency of tenseness / restlessness in last 2 weeks	1.57	1	0	0.0	0.00	1.0e+00	DAG1
Hearing difficulty/problems with background noise	1.50	2	0	0.0	0.00	1.0e+00	LIN28B SNAP91
Hair/balding pattern: Pattern 2	1.69	1	0	0.0	0.00	1.0e+00	CENPW
Forced vital capacity (FVC)	2.60	18	12	26.7	0.69	2.4e-04	ADCY3 C1QTNF4 CENPW CLEC18A FOXO6 HACE1 MTCH2 NDUFS3 NFAT5 PDXDC2P POPDC3 RP11-613D13.5 RP11-65J21.3 RP11-686O6.2 SAR1B SATB2 SENP6 WWP2
Heel bone mineral density (BMD) T-score, automated (right)	1.27	4	1	2.2	0.68	3.2e-01	C14orf39 RMND1 RP11-500G22.2 TIPARP
Ever unenthusiastic/disinterested for a whole week	1.32	1	0	0.0	0.00	1.0e+00	DAG1
Qualifications: None of the above	2.08	7	4	8.9	0.40	3.8e-01	C9orf5 DAG1 FOXO3 MED8 NEGR1 NRBF2 PIAS2
Allergy	1.23	5	0	0.0	0.52	3.7e-01	CHP DCAKD EEFSEC PSMG1 PUS10
Diabetes (self-reported)	2.02	3	0	0.0	0.00	1.0e+00	GCDH NFAT5 STAG3L2
Medication: Simvastatin	1.83	2	0	0.0	0.00	1.0e+00	BVES RP11-686O6.2
Fluid intelligence score	2.23	9	4	8.9	0.13	7.0e-01	C1QTNF4 DAG1 FOXO3 FOXO6 MED8 MTCH2 NDUFS3 NEGR1 NR1H3
Neuroticism score	1.94	4	3	6.7	0.60	2.8e-01	ARNTL ASCC3 C1QTNF4 MTCH2
Weight	3.24	28	20	44.4	-0.46	6.1e-03	ADCY3 AKTIP ASCC3 ASPHD1 BYSL C14orf39 C1QTNF4 CENPW DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MED20 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C REXO1 RMND1 RP11-152H18.3 RP11-613D13.5 STAG3L2
Impedance of arm (right)	3.18	31	23	51.1	0.66	8.8e-06	AKTIP ASCC3 ASPHD1 BVES CENPW DAG1 DCAKD DLGAP1-AS2 EEFSEC FIBP FOXO3 GAB2 GPRC5B HACE1 HEMK1 KLF16 LIN28B MAP2K5 NEGR1 NRBF2 OLFM2 PMS2P3 POM121C POPDC3 PSMG1 REXO1 SAR1B SATB2 STAG3L2 TIPARP TMEM110
Arm fat percentage (right)	5.50	31	23	51.1	-0.75	5.6e-08	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CENPW CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B STAG3L2 WWP2
Trunk fat-free mass	2.63	22	16	35.6	0.09	6.8e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MED20 MTCH2 NDUFS3 NEGR1 REXO1 RMND1 RP11-65J21.3 TMEM110
Hip circumference	3.65	27	24	53.3	-0.50	2.8e-03	ADCY3 AKTIP ASPHD1 BYSL C14orf39 C1QTNF4 CLEC18A DAG1 FOXO3 GPRC5B KLF16 MAP2K5 MAST3 MED20 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-613D13.5 STAG3L2 WWP2
Alcohol intake versus 10 years previously	1.40	2	0	0.0	0.00	1.0e+00	ASPHD1 NEGR1
Father's age at death	1.23	1	0	0.0	0.00	1.0e+00	ANXA2
Worrier / anxious feelings	1.64	3	0	0.0	0.00	1.0e+00	ARNTL SATB2 TMEM110
Frequency of tiredness / lethargy in last 2 weeks	1.78	2	1	2.2	0.00	1.0e+00	DAG1 MTCH2
Hair/balding pattern: Pattern 3	1.50	2	1	2.2	0.00	1.0e+00	CENPW DCAKD
Number of live births	1.15	1	0	0.0	0.00	1.0e+00	RMND1
Forced expiratory volume in 1-second (FEV1)	2.23	16	9	20.0	0.64	1.8e-03	ADCY3 C1QTNF4 CENPW CLEC18A DAG1 FOXO6 HACE1 HDHD2 MTCH2 NDUFS3 NFAT5 PDXDC2P POPDC3 RP11-65J21.3 SAR1B WWP2
Pulse rate	1.41	2	0	0.0	0.00	1.0e+00	DAG1 TMEM110
Qualifications: A levels/AS levels or equivalent	1.75	8	4	8.9	-0.04	9.3e-01	DAG1 HDHD2 MAST3 MED8 NEGR1 NRBF2 PIAS2 PMS2P3
Mouth/teeth dental problems: Dentures	1.72	3	0	0.0	0.00	1.0e+00	ADCY3 DAG1 LOC339803
Asthma	1.19	2	0	0.0	0.00	1.0e+00	CHP EEFSEC
Forced expiratory volume in 1-second (FEV1), Best measure	2.25	17	7	15.6	0.64	1.3e-03	ADCY3 C1QTNF4 CENPW CLEC18A DAG1 FOXO6 HDHD2 MTCH2 NDUFS3 NFAT5 PDXDC2P PIAS2 POPDC3 RP11-65J21.3 SAR1B SATB2 WWP2
Impedance of arm (left)	3.08	31	20	44.4	0.65	4.4e-05	AKTIP ASCC3 ASPHD1 BVES CENPW DAG1 DCAKD DET1 DLGAP1-AS2 EEFSEC FIBP FOXO3 GAB2 GPRC5B HACE1 HEMK1 KLF16 LIN28B MAP2K5 NEGR1 NRBF2 OLFM2 PMS2P3 POM121C POPDC3 REXO1 SAR1B SATB2 STAG3L2 TIPARP TMEM110
Arm fat mass (right)	4.74	29	25	55.6	-0.67	6.5e-06	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MED20 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Trunk predicted mass	2.63	23	16	35.6	0.07	7.2e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B LOC339803 MED20 MTCH2 NDUFS3 NEGR1 REXO1 RMND1 RP11-65J21.3 TMEM110
Standing height	3.37	44	32	71.1	0.74	4.8e-12	ADCY3 ASPHD1 BEND6 BVES BYSL C11orf63 C14orf39 C1QTNF4 CC2D2B CENPW CHP CLEC18A COG6 DCAKD DET1 ENSA FIBP FOXO3 FOXO6 GCDH HACE1 HDHD2 HEMK1 LIN28B MED20 MTCH2 NDUFS3 NFAT5 NR1H3 NRBF2 PDXDC2P PIAS2 PMS2P3 POPDC3 PRICKLE4 RMND1 RP11-500G22.2 RP11-65J21.3 RP11-686O6.2 SAR1B SENP6 SNAP91 UPK1A WWP2
Exposure to tobacco smoke at home	1.25	1	0	0.0	0.00	1.0e+00	DAG1
Tense / 'highly strung'	1.28	1	0	0.0	0.00	1.0e+00	ASCC3
Seen doctor (GP) for nerves, anxiety, tension or depression	1.87	2	1	2.2	0.00	1.0e+00	DAG1 NEGR1
Hair/balding pattern: Pattern 4	1.34	3	2	4.4	0.00	1.0e+00	C17orf89 CENPW DCAKD
Birth weight of first child	1.36	2	0	0.0	0.00	1.0e+00	PMS2P3 TIPARP
Peak expiratory flow (PEF)	1.70	5	1	2.2	0.37	4.7e-01	C1QTNF4 FOXO3 NDUFS3 PPP6C RP11-65J21.3
Ever highly irritable/argumentative for 2 days	1.13	1	0	0.0	0.00	1.0e+00	DAG1
Qualifications: O levels/GCSEs or equivalent	1.52	1	0	0.0	0.00	1.0e+00	DAG1
Medication: Paracetamol	1.24	1	0	0.0	0.00	1.0e+00	DAG1
Medication for cholesterol, blood pressure or diabetes	1.69	2	0	0.0	0.00	1.0e+00	AKTIP TAF6
Glaucoma (self-reported)	1.32	1	1	2.2	0.00	1.0e+00	C14orf39
Gout (self-reported)	1.35	2	1	2.2	0.00	1.0e+00	NFAT5 WWP2
Birth weight	2.32	5	1	2.2	0.91	3.4e-02	C1QTNF4 CENPW MTCH2 NDUFS3 TIPARP
Forced vital capacity (FVC), Best measure	2.81	19	12	26.7	0.69	1.7e-04	ADCY3 C1QTNF4 CENPW CLEC18A FOXO6 HDHD2 MTCH2 NDUFS3 NFAT5 PDXDC2P PIAS2 POPDC3 RP11-613D13.5 RP11-65J21.3 RP11-686O6.2 SAR1B SATB2 SNAP91 WWP2
Body fat percentage	4.60	30	18	40.0	-0.65	2.1e-05	ADCY3 AKTIP ARNTL ASPHD1 C11orf63 C1QTNF4 CENPW CLEC18A DCAKD FOXO3 KLF16 MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 OLFM2 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SAR1B STAG3L2 WWP2
Leg fat percentage (right)	4.38	31	20	44.4	-0.77	5.3e-08	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CENPW CLEC18A DAG1 DCAKD FIBP FOXO3 MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 NRBF2 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B SENP6 STAG3L2 WWP2
Arm fat-free mass (right)	2.49	22	15	33.3	-0.14	5.1e-01	AKTIP ASCC3 ASPHD1 C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110
Comparative body size at age 10	6.60	19	14	31.1	-0.79	2.7e-06	ADCY3 AKTIP ASCC3 ASPHD1 C11orf63 C1QTNF4 CCDC65 FIBP GPRC5B HACE1 LEPROT LIN28B LL22NC03-86G7.1 MADD MAP2K5 MTCH2 NDUFS3 NEGR1 NR1H3
Worry too long after embarrassment	1.44	2	1	2.2	0.00	1.0e+00	ARNTL MAP2K5
Wheeze or whistling in the chest in last year	1.49	3	0	0.0	0.00	1.0e+00	ASPHD1 DAG1 DCAKD
Age at first live birth	1.46	3	1	2.2	0.00	1.0e+00	DAG1 NRBF2 SAR1B
Qualifications: College or University degree	1.98	10	5	11.1	-0.30	3.8e-01	C9orf5 DAG1 FOXO3 FOXO6 MAST3 MED8 NEGR1 PMS2P3 POM121C UPK1A
Neck or shoulder pain in last month	1.73	1	0	0.0	0.00	1.0e+00	DAG1
Medication: Blood pressure	1.51	1	0	0.0	0.00	1.0e+00	KLF16
Medication: Allopurinol	1.24	1	0	0.0	0.00	1.0e+00	WWP2
Mean time to correctly identify matches	1.74	4	2	4.4	0.17	8.3e-01	ADCY3 CCDC65 FOXO3 KIF18A
Whole body fat mass	4.08	30	24	53.3	-0.69	7.5e-06	ADCY3 AKTIP ARNTL ASPHD1 C11orf63 C1QTNF4 CLEC18A DAG1 FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MED20 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SH3YL1 STAG3L2 WWP2
Leg fat mass (right)	4.27	29	23	51.1	-0.78	1.5e-07	ADCY3 AKTIP ARNTL ASCC3 ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SAR1B STAG3L2 WWP2
Arm predicted mass (right)	2.51	22	15	33.3	-0.14	5.0e-01	AKTIP ASCC3 ASPHD1 C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110
Pulse rate, automated reading	2.10	17	5	11.1	-0.48	1.9e-02	BVES BYSL CCDC65 DAG1 GAB2 GPRC5B MED20 MSH6 NEGR1 NFAT5 PMS2P3 POM121C PRICKLE4 STAG3L2 TAF6 TMEM110 WWP2
Alcohol intake frequency.	2.13	9	5	11.1	-0.98	1.5e-07	ASPHD1 C1QTNF4 MTCH2 NDUFS3 NEGR1 NFAT5 SENP6 STAG3L2 WWP2
Comparative height size at age 10	2.03	17	10	22.2	-0.36	1.4e-01	ADCY3 AKAP8 ASPHD1 C14orf39 C1QTNF4 CENPW CHP FOXO3 FOXO6 KIF18A LL22NC03-86G7.1 MED8 MTCH2 NDUFS3 NUCB2 SH3YL1 WARS
Suffer from 'nerves'	2.75	5	5	11.1	0.93	2.6e-03	C1QTNF4 MTCH2 NDUFS3 NR1H3 SATB2
Overall health rating	1.44	3	1	2.2	0.00	1.0e+00	DAG1 DCAKD STAG3L2
Chest pain or discomfort	1.58	1	0	0.0	0.00	1.0e+00	DAG1
Age at last live birth	1.48	2	1	2.2	0.00	1.0e+00	DAG1 SAR1B
Leg pain on walking	1.06	1	0	0.0	0.00	1.0e+00	DAG1
Commuting to job workplace: Car/motor vehicle	1.14	1	0	0.0	0.00	1.0e+00	NEGR1
Illness, injury, bereavement, stress in last 2 years	1.10	1	0	0.0	0.00	1.0e+00	SNAP91
Supplements: Vitamin C	1.51	2	0	0.0	0.00	1.0e+00	PRICKLE4 WWP2
Knee pain experienced in last month	1.53	1	0	0.0	0.00	1.0e+00	DAG1
Hypertension (Self-reported)	1.89	12	2	4.4	-0.52	7.0e-02	ARNTL DCAKD KLF16 MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 REXO1 STAG3L2 TAF6
Illnesses of father: Heart disease	1.30	1	0	0.0	0.00	1.0e+00	CHP
Smoking status: Previous	2.04	2	0	0.0	0.00	1.0e+00	MAP2K5 MSH6
Forced expiratory volume in 1-second (FEV1), predicted	2.63	7	2	4.4	0.70	7.9e-02	C11orf63 C1QTNF4 CENPW HEMK1 LIN28B MTCH2 NDUFS3
Whole body fat-free mass	2.60	25	17	37.8	-0.05	7.9e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110
Leg fat-free mass (right)	2.72	25	17	37.8	-0.12	5.3e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 FOXO3 FOXO6 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 NR1H3 PMS2P3 POM121C PRICKLE4 REXO1 RMND1 RP11-613D13.5 TMEM110
Arm fat percentage (left)	5.76	29	24	53.3	-0.77	3.9e-08	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CENPW CLEC18A FIBP GPRC5B KLF16 MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B STAG3L2 WWP2
Mood swings	1.67	3	0	0.0	0.00	1.0e+00	ASCC3 DAG1 MTCH2
Loneliness, isolation	1.86	4	1	2.2	0.66	2.3e-01	ASCC3 C1QTNF4 MTCH2 NDUFS3
Long-standing illness, disability or infirmity	2.35	3	0	0.0	0.00	1.0e+00	NEGR1 NFAT5 STAG3L2
Ever had bowel cancer screening	1.91	1	1	2.2	0.00	1.0e+00	PRICKLE4
Diabetes diagnosed by doctor	2.03	7	0	0.0	-0.99	4.5e-05	AKTIP CENPW CLEC18A GCDH NFAT5 PDXDC2P STAG3L2
Friendships satisfaction	1.65	1	0	0.0	0.00	1.0e+00	RP11-65J21.3
Qualifications: nursing, teaching	1.39	1	1	2.2	0.00	1.0e+00	NEGR1
Mineral and other dietary supplements	2.32	4	0	0.0	0.47	4.2e-01	BYSL MED20 NFAT5 PRICKLE4
Asthma (self-reported)	1.16	1	0	0.0	0.00	1.0e+00	EEFSEC
Smoking status: Current	1.94	3	0	0.0	0.99	1.0e-02	C1QTNF4 MTCH2 PPP6C
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.40	3	0	0.0	0.00	1.0e+00	DAG1 NFAT5 WWP2
Whole body water mass	2.62	25	17	37.8	-0.06	7.6e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110
Leg predicted mass (right)	2.72	25	17	37.8	-0.17	3.9e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MADD MAP2K5 MED20 NEGR1 NR1H3 PMS2P3 POM121C PRICKLE4 REXO1 RMND1 RP11-613D13.5 TMEM110
Arm fat mass (left)	4.79	29	25	55.6	-0.67	6.5e-06	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MED20 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 STAG3L2 WWP2
Number of self-reported non-cancer illnesses	1.71	4	2	4.4	-1.00	1.3e-03	ARNTL NEGR1 NFAT5 STAG3L2
Miserableness	2.16	4	2	4.4	1.00	6.1e-05	ARNTL C1QTNF4 DAG1 MTCH2
Guilty feelings	2.01	2	1	2.2	0.00	1.0e+00	ARNTL LIN28B
Commuting to job workplace: Public transport	1.06	1	0	0.0	0.00	1.0e+00	NEGR1
Eye problems/disorders: Glaucoma	1.34	1	1	2.2	0.00	1.0e+00	C14orf39
Supplements: Fish oil (including cod liver oil)	1.85	2	0	0.0	0.00	1.0e+00	DCAKD NFAT5
High cholesterol (Self-reported)	1.56	2	1	2.2	0.00	1.0e+00	RP11-686O6.2 SPPL3
Medication: Paracetamol	1.17	2	0	0.0	0.00	1.0e+00	DAG1 DCAKD
Ever smoked	1.91	4	1	2.2	0.49	5.1e-01	DAG1 MSH6 PPP6C PSMG1
Basal metabolic rate	2.68	25	16	35.6	-0.10	6.1e-01	AKTIP ASCC3 ASPHD1 BYSL C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 LIN28B MADD MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110
Leg fat percentage (left)	4.56	31	21	46.7	-0.77	5.5e-08	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CENPW CLEC18A DAG1 DCAKD FIBP FOXO3 MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 NRBF2 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 RP11-686O6.2 SAR1B SENP6 STAG3L2 WWP2
Arm fat-free mass (left)	2.57	21	15	33.3	-0.20	3.4e-01	AKTIP ASCC3 ASPHD1 C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3
Number of operations (self-reported)	1.44	2	0	0.0	0.00	1.0e+00	DAG1 LIN28B
Average weekly beer plus cider intake	2.77	5	1	2.2	-0.06	9.0e-01	BYSL DAG1 DCAKD NRBF2 PRICKLE4
Fractured/broken bones in last 5 years	1.19	1	0	0.0	0.00	1.0e+00	COG6
Diastolic blood pressure, automated reading	1.64	13	5	11.1	-0.65	1.2e-02	ARNTL DCAKD FIBP MAP2K5 MAST3 MED8 NRBF2 PMS2P3 POM121C REXO1 STAG3L2 STXBP5 TAF6
Ever depressed for a whole week	0.99	1	0	0.0	0.00	1.0e+00	DAG1
Myopia	1.61	2	0	0.0	0.00	1.0e+00	C14orf39 SH3YL1
Vascular/heart problems diagnosed by doctor	1.87	11	3	6.7	0.80	2.0e-03	ARNTL DCAKD KLF16 MAP2K5 NEGR1 NFAT5 NRBF2 NUCB2 PMS2P3 RP11-613D13.5 STAG3L2
Cholesterol lowering medication	1.65	2	0	0.0	0.00	1.0e+00	NUCB2 SPPL3
Medication: Omeprazole (e.g. Zanprol)	1.99	1	0	0.0	0.00	1.0e+00	MED20
Pain experienced in last month	1.55	4	2	4.4	-0.67	3.3e-01	CENPW DAG1 PPP6C RP11-613D13.5
Pack years of smoking	1.62	1	0	0.0	0.00	1.0e+00	CLEC18A
Impedance of whole body	3.29	33	22	48.9	0.60	1.9e-04	ADCY3 AKTIP ASCC3 ASPHD1 CENPW CLEC18A DAG1 DCAKD DLGAP1-AS2 FIBP FOXO3 GAB2 GPRC5B HACE1 HEMK1 KLF16 LIN28B MAP2K5 MED20 NEGR1 NRBF2 OLFM2 PDXDC2P PMS2P3 POM121C POPDC3 REXO1 SAR1B SATB2 SFI1 STAG3L2 TMEM110 WARS
Leg fat mass (left)	4.32	29	23	51.1	-0.78	1.2e-07	ADCY3 AKTIP ARNTL ASPHD1 C1QTNF4 CLEC18A DAG1 FIBP FOXO3 GPRC5B KLF16 MADD MAP2K5 MAST3 MTCH2 NDUFS3 NEGR1 NFAT5 NR1H3 PDXDC2P PMS2P3 POM121C PSMG1 REXO1 RP11-152H18.3 RP11-613D13.5 SAR1B STAG3L2 WWP2
Arm predicted mass (left)	2.53	22	14	31.1	-0.15	4.7e-01	AKTIP ASCC3 ASPHD1 C14orf39 CENPW CHP DAG1 DCAKD FOXO3 FOXO6 GPRC5B KLF16 MAP2K5 MED20 NEGR1 PMS2P3 POM121C REXO1 RMND1 RP11-613D13.5 RP11-65J21.3 TMEM110

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	25	0.72	2.6
GTEx	Adipose Visceral Omentum	19	0.93	2.6
GTEx	Adrenal Gland	4	0.27	2.4
GTEx	Artery Aorta	19	0.64	2.5
GTEx	Artery Coronary	8	0.68	2.5
GTEx	Artery Tibial	28	0.74	2.5
GTEx	Brain Caudate basal ganglia	7	0.76	2.5
GTEx	Brain Cerebellar Hemisphere	10	0.67	2.5
GTEx	Brain Cerebellum	14	0.71	2.6
GTEx	Brain Cortex	5	0.48	2.5
GTEx	Brain Frontal Cortex BA9	7	0.76	2.6
GTEx	Brain Hippocampus	1	0.19	2.5
GTEx	Brain Hypothalamus	2	0.34	2.3
GTEx	Brain Nucleus accumbens basal ganglia	3	0.35	2.4
GTEx	Brain Putamen basal ganglia	3	0.48	2.3
GTEx	Breast Mammary Tissue	16	0.81	2.5
GTEx	Breast Mammary Tissue (Male)	5	0.42	2.2
GTEx	Breast Mammary Tissue (Female)	10	0.61	2.4
GTEx	Cells EBV-transformed lymphocytes	11	0.77	2.8
GTEx	Cells Transformed fibroblasts	30	0.71	2.5
GTEx	Colon Sigmoid	11	0.75	2.5
GTEx	Colon Transverse	13	0.63	2.5
GTEx	Esophagus Gastroesophageal Junction	9	0.62	2.6
GTEx	Esophagus Mucosa	22	0.66	2.5
GTEx	Esophagus Muscularis	23	0.71	2.6
GTEx	Heart Atrial Appendage	15	0.95	2.6
GTEx	Heart Left Ventricle	15	0.98	2.6
GTEx	Liver	2	0.28	2.1
GTEx	Lung	29	1.01	2.7
GTEx	Muscle Skeletal	27	0.93	2.6
GTEx	Nerve Tibial	28	0.65	2.5
GTEx	Ovary	5	0.55	2.7
GTEx	Pancreas	7	0.43	2.4
GTEx	Pituitary	7	0.63	2.4
GTEx	Prostate	3	0.36	2.5
GTEx	Skin Not Sun Exposed Suprapubic	17	0.69	2.5
GTEx	Skin Sun Exposed Lower leg	19	0.52	2.5
GTEx	Small Intestine Terminal Ileum	4	0.87	2.4
GTEx	Spleen	6	0.43	2.4
GTEx	Stomach	14	0.96	2.6
GTEx	Testis	22	0.70	2.4
GTEx	Thyroid	26	0.65	2.6
GTEx	Uterus	0	0.00	2.4
GTEx	Vagina	1	0.16	2.4
GTEx	Whole Blood	9	0.45	2.4
METSIM	Adipose	23	0.50	2.2
NTR	Blood	9	0.37	2.2
ROSMAP	Brain Pre-frontal Cortex	43	0.98	2.4
YFS	Blood	23	0.50	2.1
CommonMind	Brain Pre-frontal Cortex	35	0.65	2.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	2.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	27	0.61	2.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.46	2.4
The Cancer Genome Atlas	Colon Adenocarcinoma	10	0.48	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.44	2.5
The Cancer Genome Atlas	Glioblastoma Multiforme	12	1.17	2.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	19	0.70	2.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	26	0.63	2.3
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	15	0.73	2.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	23	0.53	2.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	6	0.54	2.3
The Cancer Genome Atlas	Lung Adenocarcinoma	16	0.54	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	19	0.76	2.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	12	0.75	2.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.48	2.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	10	0.75	2.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	27	0.58	2.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	4	0.58	2.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	10	0.94	2.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	7	1.31	2.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	14	0.83	2.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	8	0.63	2.3
The Cancer Genome Atlas	Thyroid Carcinoma	33	0.64	2.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	3	0.59	2.2